Literature DB >> 29164637

Internal pilot design for balanced repeated measures.

Xinrui Zhang1, Keith E Muller2, Maureen M Goodenow3, Yueh-Yun Chi4.   

Abstract

Repeated measures are common in clinical trials and epidemiological studies. Designing studies with repeated measures requires reasonably accurate specifications of the variances and correlations to select an appropriate sample size. Underspecifying the variances leads to a sample size that is inadequate to detect a meaningful scientific difference, while overspecifying the variances results in an unnecessarily large sample size. Both lead to wasting resources and placing study participants in unwarranted risk. An internal pilot design allows sample size recalculation based on estimates of the nuisance parameters in the covariance matrix. We provide the theoretical results that account for the stochastic nature of the final sample size in a common class of linear mixed models. The results are useful for designing studies with repeated measures and balanced design. Simulations examine the impact of misspecification of the covariance matrix and demonstrate the accuracy of the approximations in controlling the type I error rate and achieving the target power. The proposed methods are applied to a longitudinal study assessing early antiretroviral therapy for youth living with HIV.
Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  UNIREP; fixed effects inference; linear mixed model; power; sample size

Mesh:

Year:  2017        PMID: 29164637      PMCID: PMC5768471          DOI: 10.1002/sim.7524

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  20 in total

1.  Re-calculating the sample size in internal pilot study designs with control of the type I error rate.

Authors:  M Kieser; T Friede
Journal:  Stat Med       Date:  2000-04-15       Impact factor: 2.373

2.  Internal pilot studies I: type I error rate of the naive t-test.

Authors:  J Wittes; O Schabenberger; D Zucker; E Brittain; M Proschan
Journal:  Stat Med       Date:  1999-12-30       Impact factor: 2.373

3.  Controlling test size while gaining the benefits of an internal pilot design.

Authors:  C S Coffey; K E Muller
Journal:  Biometrics       Date:  2001-06       Impact factor: 2.571

4.  Global hypothesis testing for high-dimensional repeated measures outcomes.

Authors:  Yueh-Yun Chi; Matthew Gribbin; Yvonne Lamers; Jesse F Gregory; Keith E Muller
Journal:  Stat Med       Date:  2011-12-09       Impact factor: 2.373

5.  Properties of internal pilots with the univariate approach to repeated measures.

Authors:  Christopher S Coffey; Keith E Muller
Journal:  Stat Med       Date:  2003-08-15       Impact factor: 2.373

6.  Variance estimation in clinical studies with interim sample size re-estimation.

Authors:  Frank Miller
Journal:  Biometrics       Date:  2005-06       Impact factor: 2.571

7.  Statistical tests with accurate size and power for balanced linear mixed models.

Authors:  Keith E Muller; Lloyd J Edwards; Sean L Simpson; Douglas J Taylor
Journal:  Stat Med       Date:  2007-08-30       Impact factor: 2.373

8.  Analytic, Computational, and Approximate Forms for Ratios of Noncentral and Central Gaussian Quadratic Forms.

Authors:  Hae-Young Kim; Matthew J Gribbin; Keith E Muller; Douglas J Taylor
Journal:  J Comput Graph Stat       Date:  2006-06-01       Impact factor: 2.302

9.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

Authors:  Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton
Journal:  N Engl J Med       Date:  2015-07-20       Impact factor: 91.245

10.  Confidence regions for repeated measures ANOVA power curves based on estimated covariance.

Authors:  Matthew J Gribbin; Yueh-Yun Chi; Paul W Stewart; Keith E Muller
Journal:  BMC Med Res Methodol       Date:  2013-04-15       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.